As of February 4, 2016, Tribute Pharmaceuticals Canada Inc. was acquired by Aralez Pharmaceuticals Inc. Tribute Pharmaceuticals Canada Inc., a specialty pharmaceutical company, engages in the acquisition, licensing, development, and promotion of healthcare products in Canada and internationally. The company focuses on various therapeutic areas, such as neurology, pain, urology, dermatology, and endocrinology/cardiology. Its products portfolio includes Cambia, a non-steroidal anti-inflammatory drug for the acute treatment of migraine attacks with or without aura in adults; and Bezalip SR, a pan-peroxisome proliferator-activated receptor activator to treat hyperlipidemia. The company also offers Soriatane for the treatment of severe psoriasis and other disorders of keratinization; and Collatamp G, a gentamicin-collagen haemostat for use as a surgical implant for haemostasis and local delivery of high doses of gentamicin. In addition, it offers NeoVisc, a proprietary product for the temporary replacement of synovial fluid in osteoarthritic joints; and Uracyst, a sodium chondroitin sulfate solution for the treatment of interstitial cystitis and non-common cystitis. The company was formerly known as Stellar Pharmaceuticals, Inc. and changed its name to Tribute Pharmaceuticals Canada Inc. in January 2013. Tribute Pharmaceuticals Canada Inc. was founded in 1978 and is headquartered in Milton, Canada.